FY2024 Earnings Forecast for APLS Issued By Zacks Research

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Investment analysts at Zacks Research lowered their FY2024 earnings per share (EPS) estimates for Apellis Pharmaceuticals in a note issued to investors on Tuesday, November 26th. Zacks Research analyst R. Department now expects that the company will post earnings per share of ($1.78) for the year, down from their prior estimate of ($1.55). The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.71) per share. Zacks Research also issued estimates for Apellis Pharmaceuticals’ Q4 2024 earnings at ($0.48) EPS, Q1 2025 earnings at ($0.44) EPS, Q2 2025 earnings at ($0.40) EPS, Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.23) EPS, FY2025 earnings at ($1.40) EPS, Q1 2026 earnings at ($0.23) EPS, Q2 2026 earnings at ($0.16) EPS, Q3 2026 earnings at ($0.13) EPS and FY2026 earnings at ($0.55) EPS.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its earnings results on Tuesday, November 5th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.14). Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The business had revenue of $196.83 million for the quarter, compared to analyst estimates of $200.00 million. During the same quarter in the prior year, the business earned ($1.17) earnings per share. The firm’s quarterly revenue was up 78.3% on a year-over-year basis.

APLS has been the topic of several other reports. Evercore ISI raised Apellis Pharmaceuticals to a “strong-buy” rating in a report on Thursday, October 31st. Oppenheimer reduced their target price on Apellis Pharmaceuticals from $65.00 to $40.00 and set an “outperform” rating on the stock in a report on Wednesday, November 6th. Wedbush increased their target price on shares of Apellis Pharmaceuticals from $38.00 to $41.00 and gave the company a “neutral” rating in a research report on Friday, August 9th. Morgan Stanley began coverage on shares of Apellis Pharmaceuticals in a research report on Thursday, November 21st. They issued an “equal weight” rating and a $31.00 price target on the stock. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Apellis Pharmaceuticals from $64.00 to $57.00 and set an “overweight” rating for the company in a research report on Friday, September 13th. Seven research analysts have rated the stock with a hold rating, eleven have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, Apellis Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $49.94.

Apellis Pharmaceuticals Price Performance

Shares of NASDAQ:APLS opened at $34.14 on Thursday. The company has a debt-to-equity ratio of 1.91, a quick ratio of 3.73 and a current ratio of 4.36. Apellis Pharmaceuticals has a 52 week low of $24.34 and a 52 week high of $73.80. The firm has a market cap of $4.25 billion, a PE ratio of -16.82 and a beta of 0.87. The firm’s fifty day moving average is $28.74 and its 200-day moving average is $35.41.

Insider Buying and Selling

In related news, Director A. Sinclair Dunlop sold 37,000 shares of Apellis Pharmaceuticals stock in a transaction on Monday, September 16th. The stock was sold at an average price of $36.23, for a total transaction of $1,340,510.00. Following the sale, the director now directly owns 100,000 shares in the company, valued at approximately $3,623,000. This trade represents a 27.01 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 6.80% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Apellis Pharmaceuticals

Several large investors have recently made changes to their positions in APLS. Virtu Financial LLC bought a new position in Apellis Pharmaceuticals during the third quarter valued at about $390,000. Old West Investment Management LLC purchased a new position in Apellis Pharmaceuticals in the third quarter valued at about $2,953,000. Toronto Dominion Bank boosted its stake in Apellis Pharmaceuticals by 4.2% in the third quarter. Toronto Dominion Bank now owns 25,622 shares of the company’s stock valued at $739,000 after acquiring an additional 1,022 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Apellis Pharmaceuticals by 1.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,810,526 shares of the company’s stock valued at $52,229,000 after acquiring an additional 22,609 shares during the period. Finally, Barclays PLC increased its stake in shares of Apellis Pharmaceuticals by 18.0% during the 3rd quarter. Barclays PLC now owns 255,897 shares of the company’s stock worth $7,381,000 after purchasing an additional 39,019 shares during the last quarter. 96.29% of the stock is owned by hedge funds and other institutional investors.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).